Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shannon Flood

Nurse Practitioner, Family Ridgeland, MS Nurse Practitioner

NPI 1548820897 CMS profile 10695807

715 Rice Rd Apt 13A, Ridgeland, MS 39157

Open in the dashboard

General payments

$8,644

388 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shannon Flood of Ridgeland, MS is reported in the CMS Open Payments database as having received $8,644 across 388 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,739 80
2024 General $2,060 78
2023 General $1,384 67
2022 General $1,693 82
2021 General $1,769 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shannon Flood
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Shannon Flood were reported at $1,739. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Shannon Flood Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,769 $124 $35–$379 $132
2022 $1,693 $141 $44–$430 $149
2023 $1,384 $154 $49–$476 $160
2024 $2,060 $165 $51–$504 $164
2025 $1,739 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $1,278 106 payments
  2. Jazz Pharmaceuticals Inc. $1,068 41 payments
  3. AstraZeneca Pharmaceuticals LP $916 21 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $878 40 payments
  5. Genzyme Corporation $876 35 payments
  6. Regeneron Healthcare Solutions, Inc. $693 24 payments
  7. Mallinckrodt Hospital Products Inc. $584 21 payments
  8. Inspire Medical Systems, Inc. $546 13 payments
  9. Actelion Pharmaceuticals US, Inc. $386 16 payments
  10. Verona Pharma, Inc. $186 13 payments
  11. Other $1,235 58 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,428 385 payments
  2. Education $216 3 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $1,115 89 payments
  2. DUPIXENT Immunology $876 35 payments
  3. XYWAV $857 33 payments
  4. DUPIXENT Inflammation And Immunology $616 21 payments
  5. OFEV Respiratory $596 36 payments
  6. ACTHAR $584 21 payments
  7. INSPIRE $546 13 payments
  8. FASENRA $505 9 payments
  9. BREZTRI $503 9 payments
  10. OFEV Respiratory $431 17 payments
  11. Other $2,909 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

741

Median for Nurse Practitioner: 389

Drug cost

$216,786

Median for Nurse Practitioner: $21,885

Branded share of claims

76.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 170 $142,658
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 34 $21,073
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 24 $10,971
Symbicort Budesonide/Formoterol Fumarate Brand 34 $7,905
Breo Ellipta Fluticasone/Vilanterol Brand 17 $6,667
Albuterol Sulfate Hfa Albuterol Sulfate Brand 186 $5,681
Spiriva Respimat Tiotropium Bromide Brand 11 $5,435
Advair Hfa Fluticasone Propion/Salmeterol Brand 12 $4,706
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 23 $4,266
Breyna Budesonide/Formoterol Fumarate Brand 14 $2,453

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$40,128

Medicare's payments for the services billed

Medicare patients

358

Average age 73

Services billed

627

198 women, 160 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 42%
Ischemic heart disease 35%
COPD 27%
Chronic kidney disease 25%
Depression 25%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $258
  • GENZYME CORPORATION $222
$480 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $237
$237 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $228
$228 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $169
$169 170 —
FASENRA
  • AstraZeneca Pharmaceuticals LP $153
$153 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

388 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record